phase readout
saveNCT07661173: A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
NOT_YET_RECRUITINGupdated 15d ago
community read0 votes
Sponsor: Anhui Provincial Cancer Hospital. Phase: PHASE2. Conditions: Non Small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that